Full Press Release Details
Important Disclosures This presentation contains forward-looking
statements about Neumora Therapeutics, Inc. (the "Company," "we," "us," or "our") within the meaning of the federal securities laws, including statements related to: Neumora's intention to
redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases; the timing, progress and plans for its
therapeutic development programs, including the timing of initiation and data read outs for its programs and studies, as well as its clinical trial and development plans; timing and expectations related to regulatory filings and interactions;
expectations and projections regarding future operating results and financial performance, including the sufficiency of its cash resources and expectation of the timing of its cash runway; its ability to create significant value and; other
statements identified by words such as "could," "expects," "intends," "may," "plans," "potential," "should," "will," "would," or similar
expressions and the negatives of those terms. Other than statements of historical facts, all statements contained in this presentation are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. These statements are subject to risks and uncertainties that could cause the actual results to be materially different from the information expressed or implied by these forward-looking statements, including, among
others: the risks related to the inherent uncertainty of clinical drug development and unpredictability and lengthy process for obtaining regulatory approvals; risks related to the timely initiation and enrollment in our clinical trials; risks
related to our reliance on third parties, including CROs; risks related to serious or undesirable side effects of our therapeutic candidates; risks related to our ability to utilize and protect our intellectual property rights; and other matters
that could affect sufficiency of capital resources to fund operations. For a detailed discussion of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks
relating to Neumora's business in general, please refer to the risk factors identified in the Company's filings with the Securities and Exchange Commission (SEC), including but not limited to its Registration Statement on Form S-1, as
amended (File No. 333-274229), filed with the SEC on September 11, 2023, and related Prospectus dated September 14, 2023 filed under 424(b)(4) of the Securities Act of 1933, as amended. Forward-looking statements speak only as of the date hereof,
and, except as required by law, Neumora undertakes no obligation to update or revise these forward-looking statements. 2
Our Mission We are focused on redefining neuroscience drug development
by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases 3 3
We Have Built A Leading Neuroscience Company $650M in private
capital raised, including $100M+ each from ARCH and Amgen Assembled pipeline of 7 novel CNS programs supported by long-dated composition of matter patents, into 2041+ 2019 - 2022 Built at Scale Led by experienced company
builders and leading neuroscience drug developers Built precision toolbox to increase probability of success in difficult-to -treat patient populations Navacaprant (KORA): Announced robust Phase 2 data and initiated Phase 3 pivotal
program 2023 NMRA-266 (M4 PAM): Initiated Phase 1 study in healthy volunteers Focused NMRA-511 (V1aR antagonist): Initiated Phase 1 SAD/MAD study Execution Completed IPO providing cash runway into 2026 Navacaprant:
KOASTAL-1 topline data in MDD (2H24) KOASTAL-2, KOASTAL-3 topline data in MDD (1H25) Phase 2 data in BPD (2025) 2024 - 2025 NMRA-266: Value-Creating Catalysts Phase 1 data in healthy volunteers
(mid-2024) Phase 1b data in schizophrenia (2025) NMRA-511: Phase 1b data in Alzheimer's agitation (2025) 4 4
Tackling One of the Largest Population Health Markets with Potential for
Significant Patient Impact Starting in 2026 Neumora has potential to address up to ~40M+ patients starting in 2026 with a robust IP runway into 2041+ 1 Biggest Health Disorders Facing U.S. Patients Impacted (M) ~40M+ Patient Opportunity 0 20 40 60
80 100 120 140 Diabetes, Obesity & NMRA-511 NMRA-511 Metabolic Disease Alzheimer's Alzheimer's Agitation Agitation Heart Disease & Stroke NMRA-266 NMRA-266 Neuropsychiatry & Schizophrenia Schizophrenia Neurodegenerative
Disease* Neumora is focused on Infectious Disease Navacaprant Navacaprant one of the largest BPD BPD population health markets 21M facing the US Traumatic Brain Patient Opportunity Injury Navacaprant Navacaprant Cancer MDD MDD Neumora Focus Area
Other Population Health Issue 2030 2026 1 National Institutes of Health. Our Biggest Health Challenges. Accessed December 2023. Note: Figure not intended as launch guidance or order. BPD = Bipolar Depression; MDD = major depressive disorder.
*Includes: MDD, BPD, Schizophrenia, Generalized Anxiety Disorder, Post Traumatic Stress Disorder, Substance Use Disorder, Alzheimer's Disease, Parkinson's Disease, Attention-Deficit Hyperactivity Disorder 5 Potential Marketed Products & Total US
Advancing a Leading Neuroscience Pipeline PROGRAM INDICATION
Broad pipeline addressing Target/Mechanism U.S. Prevalence Preclinical Phase 1 Phase 2 Phase 3 some of the most prevalent brain Neuropsychiatry Programs health disorders Major Depressive Disorder 21M Navacaprant (NMRA-140) Targeting novel
mechanisms KOR Antagonist Bipolar Depression across a broad range of 7M neuropsychiatric and neurodegenerative indications NMRA-266 Schizophrenia 3M M4 Modulator Scaling pipeline through internal Agitation in NMRA-511 Alzheimer's
Disease discovery efforts and business V1aR Antagonist 6M development activities NMRA-NMDA Schizophrenia 3M NMDA Modulator Strong IP with worldwide Neurodegeneration Programs rights to all programs into the ALS/Alzheimer's 2040s
NMRA-CK1 Disease CK1 Inhibitor 25K/6M NMRA-NLRP3 Parkinson's Disease 1M NLRP3 Inhibitor Parkinson's Disease NMRA-GCASE 1M GCase Activator ALS = Amyotrophic lateral sclerosis; CK1 = Casein Kinase I Isoform delta; GCase =
Glucocerebrosidase; IP = Intellectual Property; KOR = kappa opioid receptor; M4R = Muscarinic Acetylcholine Receptor M4; NLRP3 = Nucleotide-binding Domain, Leucine-rich-containing Family, Pyrin Domain-containing-3; NMDA =
N-methyl-D-aspartate; V1aR = Vasopressin 1a Receptor. *All dates are approximate / estimates / projections only 6
Clinical Stage Neuropsychiatry Portfolio Pursuing Large Markets with
Clinically Validated Targets Differentiated programs with broad potential Navacaprant NMRA-266 NMRA-511 M4 Receptor Positive Allosteric Mechanism Kappa Opioid Receptor Antagonist V1a Receptor Antagonist Modulator Stage Phase 3 Phase 1 Phase 1b
Best-in-Class Pharmacology First-in-Class Mechanism Market Opportunity 75M+ patients 25M+ patients 20M+ patients IP Protection Composition of Matter into 2041+ Composition of Matter into 2042+ Composition of Matter into 2043+ Clinical Validation
Market Participants Multi-Billion Sales Potential 7
Advancing an Exciting Set of Preclinical Programs Strong biological
rationale NMRA-CK1 NMRA-NLRP3 NMRA-GCase NMRA-NMDA NMDA Positive Allosteric Mechanism CK1 Inhibitor NLRP3 Inhibitor GCase Activator Modulator Potential Indications ALS, Alzheimer's Disease Parkinson's Disease
Parkinson's Disease Schizophrenia Origin Internally Developed Internally Developed 8
Navacaprant is the Best-in-Class Kappa Opioid Receptor Antagonist with a
Differentiated Clinical Profile Expected Upcoming Program Milestones Navacaprant Profile Selective KOR antagonist with >300-fold selectivity for KOR over MOR and 90% receptor 2024 1,2 occupancy coverage Topline data from KOASTAL-1
study (2H24) Clinical validation for KOR agonists from 3 Initiate Phase 2 clinical study in bipolar independent sponsors depression (1H24) Oral, once-daily 80 mg dose with no titration required Exclusivity through
2041, based on composition of 2025 matter protection Topline data readout from KOASTAL-2 and Robust Phase 2 data in MDD show efficacy in KOASTAL-3 studies (1H25) core symptoms including anhedonia, well-tolerated safety profile
NDA submission in MDD monotherapy (2025) Strong rationale in BPD Topline data readout from Phase 2 in BPD (2025) 1 2 Morrison FG, et al. Poster SoBP. 2023. Wallace TL, et al. Poster ACNP 2019. KOR = kappa opioid receptor; MOR
= mu opioid receptor; BPD = Bipolar Depression; HAMD-17 = Hamilton Rating Scale for Depression; MDD = major depressive disorder; SHAPS = Snaith-Hamilton Pleasure Scale. 9
Navacaprant Pharmacology Differentiated from Other Kappa Opioid
Receptor Antagonists in Clinical Development 1,2 3,4 5,6 Navacaprant Aticaprant CVL-354 Binding Selectivity ~310x selectivity ~30x selectivity 31x selectivity (Ki nM) for KOR over MOR for KOR over MOR for KOR over MOR KOR Receptor 95-87% receptor
target 94-73% receptor target Estimated 85% at Occupancy at coverage for ~24 hours coverage for ~24 hours 175 g/kg in NHP* Therapeutic Dose Human t >30 hours 30 - 40 hours Under investigation 1/2 6 *175 g/kg was the highest dose
used to estimate Kappa receptor occupancy in nonhuman primates (NHP) ; CVL-354 starting dose of 25 mg for KOR R/O and 150 mg for MOR R/O are being investigated in their phase 1 PET study in healthy volunteers estimated completion JUN2024
(www.clinicaltrials.gov accessed 6MAR23) DOR, delta opioid receptor; IC , half maximal inhibitory concentration; Ki, inhibitor constant; KOR, kappa opioid receptor; MOA, mechanism of action; MOR, mu opioid receptor. 50 1. Guerrero M, et al. J Med
Chem. 2019;62(4):1761-1780. 2. Neumora. Data on File. 3. Rorick-Kehn LM, et al. Neuropharmacology. 2014;77:131-144. 4. Lowe SL, et al. J Clin Pharmacol. 2014;54(9):968-978. 5. Missig G. CVL-354, a Novel, Brain Penetrant and Selective Kappa Opioid
Receptor Antagonist. Poster presented at: American College of Neuropsychopharmacology, October 13-15, 2022; Tampa, FL. 6. Duvvuri S. Evaluation of Kappa and Mu Opioid Receptor Occupancy by CVL-354 Using PET in Nonhuman Primates. Poster presented at:
American College of Neuropsychopharmacology, October 13-15, 2022; Tampa, FL. ANCP poster. 10
First Program to Demonstrate Efficacy in Symptoms of Depression and
Anhedonia HAMD-17 Week 0 Week 4 Week 8 Safety profile with significant advantages 0 over existing treatment options Robust Phase 2 Data -2 Study included 40 sites in the U.S. -4 TEAEs Incidence ( 2% in either treatment group)
204 patients enrolled in the study, 100 -5.5 -6 patients included in pre-specified -7.1 Placebo Navacaprant moderate-to-severe population -8 n=102 n=102 -8.5 Statistically significant results seen on -9.9 -10 Preferred Terms n (%) n (%) both
depression and anhedonia in LSM = -3.0 LSM = -2.8 moderate-to-severe patients with MDD -12 P = 0.015 P = 0.037 Headache 5 (4.9) 5 (4.9) Efficacy demonstrated across additional SHAPS outcome measures in the moderate-to- COVID-19 3
(2.9) 4 (3.9) Week 0 Week 4 Week 8 severe MDD population, including 0 HAMD-17 response and remission rates, Nausea 1 (1.0) 5 (4.9) HAMD-6 and CGI-S -2 -4.0 Navacaprant was well tolerated and was Diarrhea 3 (2.9) 2 (2.0) -4 -4.4 not
associated with weight gain or Upper respiratory tract -6 -6.4 sexual dysfunction 1 (1.0) 3 (2.9) infection -8 No evidence of suicidal behavior was -9.2 identified as assessed the Columbia -10 Overall discontinuation rates were higher on
Suicide Severity Rating Scale LSM = -2.4 LSM = -4.8 placebo compared to navacaprant (29% -12 P = 0.071 P = 0.0006 navacaprant and 37% placebo) Navacaprant Placebo Note: Graphs depict prespecified statistical sensitivity analysis for
moderate-to-severe patients (n=100; baseline HAMD-17 22). HAMD-17 = 17-Item Hamilton Rating Scale for Depression; MDD = Major Depressive Disorder; SHAPS= Snaith-Hamilton Pleasure Scale; HAMD-17 response = a reduction of 50% on HAMD-17
score; HAMD-17 remission = HAMD-17 score 7 ; CGI-S = Clinical Global Impression Scale-Severity. 11 Change From Baseline Change From Baseline SHAPS, LS Mean (SE) HAMD-17, LS Mean (SE) Improvement Improvement
Near-term Clinical Development Plan Focused on MDD with Opportunity for
Further Expansion Navacaprant Clinical Development Programs Major Depressive Disorder Additional Bipolar Depression Neuropsych Opportunities Substance KOASTAL-LT Phase 2 Three replicate, placebo-controlled, double-blind RCTs evaluating Use Disorder
efficacy and safety of navacaprant in patients with MDD. Approach Open-label extension Placebo-controlled RCT provides increased probability of success across program. trial evaluating long-term evaluating efficacy and Schizophrenia safety of
navacaprant safety of navacaprant in in patients with MDD patients with BPD ADHD KOASTAL-2 KOASTAL-1 KOASTAL-3 Generalized Conducted in U.S. Conducted in U.S., Conducted in U.S. and Designed to enable Patients from Canada and Latin America Europe
Anxiety quick decision-making KOASTAL-1C Disorder on advancing in BPD Topline data Topline data Topline data Post-Traumatic expected in 2H24 expected in 1H25 expected in 1H25 Long-term data enables Planned 1H24 Stress Disorder NDA submission in 2025
Initiation MDD = Major Depressive Disorder; RCT = Randomized Controlled Trial; BPD = Bipolar Depression 12
KOASTAL Pivotal Study Design Well Suited for Navacaprant Pharmacology KOASTAL Pivotal Efficacy Studies Robust placebo Navacaprant 80 mg QD Opportunity minimization R to enroll in strategies include
1:1 KOASTAL-LT stringent site Placebo QD selection, substantial internal medical Randomized, double-blind treatment monitoring, use of central raters and placebo-control Baseline WK WK WK WK 1 2 4 6 reminder scripts Key Efficacy Assessments
KOASTAL-1, KOASTAL-2, KOASTAL-3 Summary Adults ages 18 - 65 diagnosed with MDD from baseline to each timepoint in CGI-S and CGI-I Inclusion Criteria: MADRS 25 at baseline from baseline to each timepoint
in PHQ-9 Other Secondary Endpoints Include: from baseline to each timepoint in HAM-A Primary Endpoint: from baseline to Week 6 in MADRS total score from baseline to each timepoint in SDS Key Exploratory from baseline
to each timepoint in the EQ-5D 5L Key Secondary Endpoint: from baseline to Week 6 in SHAPS total score Endpoints*: from baseline to each timepoint in the WPAI-GH *Safety Assessments include Change in Sexual Functioning Questionnaire
(CSFQ-14) = Change; CGI-I = Clinical Global Impression-Improvement scale; CGI-S = Clinical Global Impression-Severity scale; EQ-5D 5L = EuroQol-5D 5L; HAM-A = Hamilton Anxiety Rating Scale; MADRS = Montgomery- sberg Depression Rating Scale; MDD
= Major Depressive Disorder; PHQ-9 = Patient Health Questionnaire-9; QD = once daily; SDS = Sheehan Disability Scale; SHAPS = Snaith-Hamilton Pleasure Scale; wk = week; WPAI-GH = Work Productivity and Activity Impairment Questionnaire -
Navacaprant Would Enter Large MDD Market with a Highly Differentiated
Profile Growth in addressable MDD market expected in-line with Prescribers prefer navacaprant compared to approved agents population growth; majority of patients treated with due to novel mechanism, superior dosing and side effect profile* 1
monotherapy, ranging from 60-85% across lines of therapy U.S. MDD diagnosed, pharmacologically treated prevalent Provider preference population (2018-41F) Millions of people Approved Navacaprant Agents Profile Rationale 16 IQVIA claims data suggests
higher KOLs find the ability to target multiple patient volume of 75% of patients Novel 14 neurological circuits as a key strength using a pharmacologic treatment Mechanism of the KORA mechanism 12 10 Once-daily dosing of navacaprant Dosing provides
a competitive advantage 8 6 Selectivity profile of navacaprant will Tolerability enable optimal receptor occupancy Profile 4 2 Navacaprant treats core symptoms of Efficacy depression, anhedonia and anxiety 0 2018 2019 2020 2021 2025F 2029F 2031F
2035F 2039F 2041F IQVIA DataMonitor Degree of preference: High Medium Low 1 Kern et al. Treatment patterns and sequences of pharmacotherapy for patients diagnosed with depression in the United States: 2014 through 2019. BMC Psychiatry. (2020) 20:4.
U.S. Census Population Projections; DRG; Datamonitor; National Survey of Drug Use and Health 2018, 2019, 2020, 2021; Torre et al. (2021); L.E.K. research and analysis; IQVIA *Independent market research, interviews, and analysis using anticipated
navacaprant profile based on Phase 2 data conducted by L.E.K. Consulting, March 2023. 14
NMRA-266 is a Potentially Differentiated M4 Receptor PAM for
Schizophrenia 2 3 NMRA-266 Emraclidine Pharmacology Designed as a highly selective M4 muscarinic M EC (cAMP) 32 nM 12 nM 4 50 receptor PAM for antipsychotic-like efficacy with the potential for improved safety profile Human t Pending Phase 1 Study
9-12 h 1/2 Indication Schizophrenia [1] Brain: Plasma ratio 1:1 1:1 Epidemiology Selectivity at other M > 10 M, M 6.8 M M > 10 M, M 5.8 M Estimated 3 million patients in 1,3,5 2 1,3,5 2 M subtypes (EC ) 50 1 the U.S.
with schizophrenia Bioavailability 67% (predicted) Unknown Drug Profile Oral, once-daily Expected Upcoming Program Milestones Strong IP Protection Expect exclusivity through 2042+, based on composition of matter protection and 2024 2025
Phase 1 healthy volunteer data readout (mid-2024) Topline data readout from Phase 1b study in estimated patent term extension Initiate Phase 1b study in schizophrenia (2H24) schizophrenia (2025) 1 2 3 Wander, C. Am J Manag Care.
2020;26:S62-S68. NMRA data on file; CERE Company data. Note: Data on this slide is presented for illustrative purposes only and the data for emraclidine were not derived from Neumora clinical trials or preclinical studies. PAM = positive allosteric
NMRA-511 is a Best-in-Class V1aR Antagonist with Broad Potential Across
Neuropsychiatric Disorders 1 NMRA-511 Pharmacology Antagonist of vasopressin 1a receptor (V1aR), with high selectivity Potency 0.9 nM over V1b, V2 (greater than 3,000-fold) and oxytocin receptors (functional IC50) (approximately 300-fold)
High selectivity over V1b, V2 Vasopressin plays a role in the regulation of aggression, affiliation, Relative Selectivity (greater than 3,000-fold) and oxytocin stress and anxiety response receptors (approximately 300-fold) >90% for 10 mg
dose Indication Projected human RO >95% for 20 mg dose Agitation in Alzheimer's disease Human t ~12 hours 1/2 Drug Profile Oral, once-daily Expected Upcoming Program Milestones Strong IP Protection Expect exclusivity through 2042+, based
2024 on composition of matter protection and estimated PTE Initiate study in Alzheimer's disease agitation (1H24) Differentiation Areas for differentiation from balovaptan include structural diversity, target potency and potential target
engagement (modelled) 2025 Topline data readout in Alzheimer's disease agitation (2025) 1 NMRA Data on File.. PTE = patent term extension. 16
2024 and 2025 Are Catalyst Rich Years for Neumora Built at Scale
Leading Pipeline Innovative Approach Raised >$850M to date from leading investors with a team of Advancing seven NCE therapeutic candidates with novel MOAs Maximizing the value of our programs to potentially increase the expert company builders